TWI914404B - 利用核糖核苷酸還原酶抑制劑治療核糖核苷酸還原酶相關疾病之方法 - Google Patents

利用核糖核苷酸還原酶抑制劑治療核糖核苷酸還原酶相關疾病之方法

Info

Publication number
TWI914404B
TWI914404B TW110134367A TW110134367A TWI914404B TW I914404 B TWI914404 B TW I914404B TW 110134367 A TW110134367 A TW 110134367A TW 110134367 A TW110134367 A TW 110134367A TW I914404 B TWI914404 B TW I914404B
Authority
TW
Taiwan
Prior art keywords
inhibitors
week
compound
cancer
salts
Prior art date
Application number
TW110134367A
Other languages
English (en)
Chinese (zh)
Other versions
TW202227059A (zh
Inventor
上野裕之
星野卓哉
哈洛德 科爾
亞蘭 奧加尼西亞
Original Assignee
日商大鵬藥品工業股份有限公司
美商亞士德製藥公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 日商大鵬藥品工業股份有限公司, 美商亞士德製藥公司 filed Critical 日商大鵬藥品工業股份有限公司
Publication of TW202227059A publication Critical patent/TW202227059A/zh
Application granted granted Critical
Publication of TWI914404B publication Critical patent/TWI914404B/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
TW110134367A 2020-09-15 2021-09-15 利用核糖核苷酸還原酶抑制劑治療核糖核苷酸還原酶相關疾病之方法 TWI914404B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063078833P 2020-09-15 2020-09-15
US63/078,833 2020-09-15

Publications (2)

Publication Number Publication Date
TW202227059A TW202227059A (zh) 2022-07-16
TWI914404B true TWI914404B (zh) 2026-02-11

Family

ID=80776688

Family Applications (1)

Application Number Title Priority Date Filing Date
TW110134367A TWI914404B (zh) 2020-09-15 2021-09-15 利用核糖核苷酸還原酶抑制劑治療核糖核苷酸還原酶相關疾病之方法

Country Status (7)

Country Link
US (1) US20230338342A1 (cg-RX-API-DMAC7.html)
EP (1) EP4213841A4 (cg-RX-API-DMAC7.html)
JP (1) JP2023541430A (cg-RX-API-DMAC7.html)
KR (1) KR20230067646A (cg-RX-API-DMAC7.html)
AU (1) AU2021344091A1 (cg-RX-API-DMAC7.html)
TW (1) TWI914404B (cg-RX-API-DMAC7.html)
WO (1) WO2022059691A1 (cg-RX-API-DMAC7.html)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
US20250375445A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026050446A1 (en) 2024-08-29 2026-03-05 Revolution Medicines, Inc. Ras inhibitors
WO2026072904A2 (en) 2024-09-26 2026-04-02 Revolution Medicines, Inc. Compositions and methods for treating lung cancer
WO2026090116A2 (en) 2024-10-21 2026-04-30 Revolution Medicines, Inc. Ras inhibitors
US20260108528A1 (en) 2024-10-22 2026-04-23 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2026090245A1 (en) 2024-10-22 2026-04-30 Revolution Medicines, Inc. Use of ras inhibitors for treating cancer
WO2026106912A1 (en) 2024-11-12 2026-05-21 Revolution Medicines, Inc. Ras inhibitors
WO2026122764A2 (en) 2024-12-06 2026-06-11 Revolution Medicines, Inc. Ras inhibitors
WO2026128688A2 (en) 2024-12-13 2026-06-18 Revolution Medicines, Inc. Ras inhibitors
WO2026161839A1 (en) 2025-01-27 2026-07-30 Revolution Medicines, Inc. Ras inhibitors

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019107386A1 (ja) 2017-11-29 2019-06-06 大鵬薬品工業株式会社 抗腫瘍剤
US20200157066A1 (en) 2016-05-31 2020-05-21 Taiho Pharmaceutical Co., Ltd. Sulfonamide Compound or Salt Thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011121453A2 (en) * 2010-03-30 2011-10-06 Clavis Pharma Asa Methods and compositions for treating or ameliorating cancer using gemcitabine-5'-elaidate

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20200157066A1 (en) 2016-05-31 2020-05-21 Taiho Pharmaceutical Co., Ltd. Sulfonamide Compound or Salt Thereof
WO2019107386A1 (ja) 2017-11-29 2019-06-06 大鵬薬品工業株式会社 抗腫瘍剤

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
期刊 John Murren, et al "Phase I and pharmacokinetic study of triapine, a potent ribonucleotide reductase inhibitor, administered daily for five days in patients with advanced solid tumors." Clin Cancer Res 9(11) 2003 Sep 15 4092-4100
期刊 Kelli L Goss, et al "Gene expression signature based screening identifies ribonucleotide reductase as a candidate therapeutic target in Ewing sarcoma." Oncotarget 7(39) 2016 Sep 27 63003-63019
期刊 加藤裕久 "がん薬物療法におけるレジメン管理" Japanese Journal of Drug Informatics 2010, Vol.11, No.4 pp.217-222

Also Published As

Publication number Publication date
KR20230067646A (ko) 2023-05-16
AU2021344091A9 (en) 2024-08-08
JP2023541430A (ja) 2023-10-02
EP4213841A1 (en) 2023-07-26
US20230338342A1 (en) 2023-10-26
TW202227059A (zh) 2022-07-16
WO2022059691A1 (en) 2022-03-24
AU2021344091A1 (en) 2023-05-25
EP4213841A4 (en) 2024-07-24

Similar Documents

Publication Publication Date Title
EP4213842B1 (en) Ribonucleotide reductase inhibitor for use in a method of treating tumors
US20230338342A1 (en) Methods of treating ribonucleotide reductase-related diseases with a ribonucleotide reductase inhibitor
CN113038953B (zh) 用于治疗癌症的包括krasg12c抑制剂和一种或多种其他药学活性药剂的组合疗法
CN121487738A (zh) 诱导ras gtp水解的组合物和其用途
KR20250169290A (ko) Ras 억제제의 결정형, 이를 함유하는 조성물 및 이의 사용 방법
US20250049810A1 (en) Methods of treating a ras protein-related disease or disorder
EP4704850A1 (en) Combination therapy for a ras related disease or disorder
TW202502351A (zh) 治療ras相關疾病或病症之方法
WO2025255438A1 (en) Methods of treating a ras protein-related disease or disorder
RU2859365C2 (ru) Способы лечения заболеваний, связанных с рибонуклеотидредуктазой, ингибитором рибонуклеотидредуктазы
RU2848459C1 (ru) Способы лечения заболеваний, связанных с рибонуклеотидредуктазой, ингибитором рибонуклеотидредуктазы
TW202329934A (zh) 使用聯苯化合物及免疫檢查點分子調節劑之用於癌症的組合療法
US20240408100A1 (en) Treatment methods for subjects having cancer with a dysregulated mapk and/or pi3k pathway
WO2026015825A1 (en) Use of ras inhibitor for treating pancreatic cancer
HK40129790A (en) Combination therapy including a krasg12c inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers
WO2026015801A1 (en) Methods of treating a ras related disease or disorder
HK40055650A (en) Combination therapy including a krasg12c inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers
HK40051935A (en) Combination therapy including a kras-g12c inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers
HK40051935B (en) Combination therapy including a kras-g12c inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers